Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Burges

Showing results (81-90 of 118) with videos related to

Pageof 12
Sort By:
Journal of Cancer Research and Clinical Oncology|May 2, 2023
Nuclear receptor co-repressor NCOR2 and its relation to GPER with prognostic impact in ovarian cancerJuliane Reichenbach, Patricia Fraungruber, Doris Mayr, et al.
Current Issues in Molecular Biology|November 24, 2023
Galectin-10 Expression in Placentas of Women with Gestational DiabetesChristina Buschmann, Laura Unverdorben, Julia Knabl, et al.
Cellular Oncology (Dordrecht, Netherlands)|September 13, 2022
Presence of regulatory T-cells in endometrial cancer predicts poorer overall survival and promotes progression of tumor cellsThomas Kolben, Mareike Mannewitz, Carolin Perleberg, et al.
Archives of Gynecology and Obstetrics|December 5, 2020
NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMUElena Sultova, C Benedikt Westphalen, Andreas Jung, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 23, 2016
Phase II Study Evaluating PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecologic Sarcomas and Mixed Epithelial-Mesenchymal Tumors A Phase II Protocol of the Arbeitsgemeinschaft Gynaekologische Onkologie Study Group (AGO-GYN 7)Philipp Harter, Jalid Sehouli, Alexander Reuss, et al.
Gynecologic Oncology|May 9, 2012
Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IVWerner Meier, Andreas du Bois, Jörn Rau, et al.
Journal of Cancer Research and Clinical Oncology|September 6, 2022
High RIG-I and EFTUD2 expression predicts poor survival in endometrial cancerSusanne Beyer, Lena Müller, Sophie Mitter, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 2, 2020
Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)Philipp Harter, Patricia Pautier, Els Van Nieuwenhuysen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II studyAlexander Burges, Pauline Wimberger, Carolin Kümper, et al.
Archives of Gynecology and Obstetrics|July 21, 2021
The effect of fertility-sparing surgery on sexuality and global quality of life in women with malignant ovarian germ cell and sex cord stromal tumors: an analysis of the CORSETT database of the AGO study groupAnnette Hasenburg, Hellmut Plett, Bernhard Krämer, et al.
Pageof 12

Showing results (81-90 of 118) with videos related to

Sort By:
Pageof 12
Journal of Cancer Research and Clinical Oncology|May 2, 2023
Nuclear receptor co-repressor NCOR2 and its relation to GPER with prognostic impact in ovarian cancerJuliane Reichenbach, Patricia Fraungruber, Doris Mayr, et al.
Current Issues in Molecular Biology|November 24, 2023
Galectin-10 Expression in Placentas of Women with Gestational DiabetesChristina Buschmann, Laura Unverdorben, Julia Knabl, et al.
Cellular Oncology (Dordrecht, Netherlands)|September 13, 2022
Presence of regulatory T-cells in endometrial cancer predicts poorer overall survival and promotes progression of tumor cellsThomas Kolben, Mareike Mannewitz, Carolin Perleberg, et al.
Archives of Gynecology and Obstetrics|December 5, 2020
NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMUElena Sultova, C Benedikt Westphalen, Andreas Jung, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 23, 2016
Phase II Study Evaluating PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecologic Sarcomas and Mixed Epithelial-Mesenchymal Tumors A Phase II Protocol of the Arbeitsgemeinschaft Gynaekologische Onkologie Study Group (AGO-GYN 7)Philipp Harter, Jalid Sehouli, Alexander Reuss, et al.
Gynecologic Oncology|May 9, 2012
Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IVWerner Meier, Andreas du Bois, Jörn Rau, et al.
Journal of Cancer Research and Clinical Oncology|September 6, 2022
High RIG-I and EFTUD2 expression predicts poor survival in endometrial cancerSusanne Beyer, Lena Müller, Sophie Mitter, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 2, 2020
Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)Philipp Harter, Patricia Pautier, Els Van Nieuwenhuysen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II studyAlexander Burges, Pauline Wimberger, Carolin Kümper, et al.
Archives of Gynecology and Obstetrics|July 21, 2021
The effect of fertility-sparing surgery on sexuality and global quality of life in women with malignant ovarian germ cell and sex cord stromal tumors: an analysis of the CORSETT database of the AGO study groupAnnette Hasenburg, Hellmut Plett, Bernhard Krämer, et al.
Pageof 12